Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Oncternal Therapeutics Inc

ONCT
Current price
0.53 USD 0 USD (0.00%)
Last closed 0.53 USD
ISIN US68236P1075
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 558 546 USD
Yield for 12 month -93.79 %
1Y
3Y
5Y
10Y
15Y
ONCT
21.11.2021 - 28.11.2021

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. Address: 12230 El Camino Real, San Diego, CA, United States, 92130

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2.00 USD

P/E ratio

Dividend Yield

Current Year

+785 000 USD

Last Year

+1 490 000 USD

Current Quarter

Last Quarter

+801 000 USD

Current Year

-28 968 000 USD

Last Year

+1 490 000 USD

Current Quarter

Last Quarter

-5 100 000 USD

Key Figures ONCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA
Operating Margin TTM -1 757.29 %
Price to Earnings
Return On Assets TTM -76.45 %
PEG Ratio
Return On Equity TTM -149.86 %
Wall Street Target Price 2.00 USD
Revenue TTM 2 161 000 USD
Book Value 3.09 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 176.00 %
Dividend Yield
Gross Profit TTM -6 515 000 USD
Earnings per share -11.69 USD
Diluted Eps TTM -11.69 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ONCT

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ONCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:20
Payout Ratio TTM
Last Split Date 08.01.2024

Stock Valuation ONCT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.85
Price Sales TTM 0.72
Enterprise Value EBITDA 0.15
Price Book MRQ 0.17

Financials ONCT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ONCT

For 52 weeks

0.53 USD 9.88 USD
50 Day MA 0.53 USD
Shares Short Prior Month 45 352
200 Day MA 1.65 USD
Short Ratio 0.090
Shares Short 14 209
Short Percent 0.50 %